Taproot Health has signed memorandums of understanding with several National Cancer Institute-designated cancer centers and community oncology clinics to conduct a master observational trial with the aim of collecting and sharing data that will help advance precision oncology.
TrialSite News breaks this news down for our audience.
Who is Taproot Health?
Taproot Health, founded in 2018, is a data-as-a-service enterprise uniting all oncology stakeholders in launching a transparent data marketplace. The marketplace, resulting from the National Oncology Master Trial and clinical network, is powered by a patient and clinic-centric model of shared data and revenue mediated through proprietary methods and technology.
What is Root?
Root is a new class of master protocols known as Master Observational Trial (MOT) designed to collect regulatory-grade real-world data benefiting all stakeholders in cancer care,” reports Dane J. Dickson, MD, Tapoot Health’s co-founder and Chief Executive Officer.
What Cornerstone Centers have agreed to work with the company?
· National Cancer Institute-Designated Cancer Centers
· University of California at San Diego Moores Cancer Center
· San Diego, California The Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, Pennsylvania
· The Knight Cancer Institute at Oregon Health Science University
· Portland, Oregon Community Oncology Clinics:
· Utah Cancer Specialists, Salt Lake City, Utah
· Teton Cancer Institute, Idaho Falls, Idaho
What is the core nature of this partnership?
According to Dickson, “We will all work together to further build and expand data collection and sharing efforts to create a sustainable system that will allow researchers access to patient consented, high-quality data tied to prospectively obtained patient outcomes.” The effort, according to Taproot Health, will be transformative in the world of precision medicine, where cancer treatment is tailored to an individual patient.
These first centers are hoped to bring advances in the mission to develop personalized treatments for every patient.
Principal Investigator Comments
Razelle Kurzrock, MD Director, Center for Personalized Cancer Therapy at the University of California, San Diego and principal investigator of ROOT, noted, “The data will provide the large-scale, high quality- evidence to answer complex questions that can be solved in no other way.”
Jennifer Johnson, MD, PhD, Precision Medicine, Director, Department of Medical Oncology, Thomas Jefferson University Hospital in Philadelphia and principal investigator, reports, “Precision Oncology is stunted when critical patient data is not broadly shared. The ROOT MOT will serve as the foundational effort to collect and share the standardized and quality data that is needed to rapidly advance precision oncology.”
Representing community oncology clinics, Randy Erickson, RN, BSN, MBA, Chief Executive Officer, Utah Cancer Specialists, commented that “the importance of the involvement of community practices cannot be underestimated.”Source: Genome Web